| Similar Articles |
|---|
 |
The Motley Fool
December 7, 2007
Brian Lawler |
Pain Continues as Planned Pain Therapeutics reports on a successful phase 3 trial for its lead drug Remoxy.   |
The Motley Fool
July 18, 2007
Brian Orelli |
Pain-Free Payday for DURECT Results from a trial take it one step closer to possible approval for a local anesthetic. Because the platform can be used with different types of drugs, DURECT could try to win additional partnerships. |
The Motley Fool
January 6, 2012
David Williamson |
Durect Investors Feel the Pain A phase 3 failure of a lead drug crushes shares. |
The Motley Fool
November 30, 2006
Brian Lawler |
Durect's Pain-Free Deal A partnership deal has investors in the small specialty pharma excited. |
The Motley Fool
May 29, 2007
Brian Lawler |
The One Development-Stage Drug Stock to Own Now With such a low level of Remoxy sales baked into its share price, and minimal clinical trial risk, investors who consider Pain Therapeutics around today's share price won't be hurting in the long run, if you assume there will be a viable market for abuse-resistant opioids. |
The Motley Fool
May 2, 2007
Brian Lawler |
Another Free Quarter of Pain If the Remoxy abuse-resistant platform technology produces more positive clinical trial results later in the year, investors should have plenty to cheer about. |
The Motley Fool
June 27, 2011
Brian Orelli |
Double Ouch! 2 Monster Drops in 2 Trading Days Perhaps investors in Pain Therapeutics and DURECT would have rather been kept in the dark about these FDA rejections. |
The Motley Fool
April 2, 2007
Brian Lawler |
Pain Therapeutics Pares Shares The small drugmaker announces a share buyback. |
The Motley Fool
June 24, 2011
Brian Orelli |
Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why? |
The Motley Fool
May 28, 2008
Brian Lawler |
King Pays a Modest Ransom King Pharmaceuticals, a prolific acquirer of other companies' drugs, announces that it had painlessly staked its claim to yet another. |
The Motley Fool
November 10, 2005
W.D. Crotty |
Portfolio Pain Relief Pain Therapeutics announces a significant development deal with King Pharmaceuticals. The company's stock is the largest percentage gainer on the Nasdaq -- up 48.9%. |
The Motley Fool
December 11, 2008
Brian Orelli |
A Painful Letter from the FDA The FDA smacked down King Pharmaceuticals and Pain Therapeutics with a complete response letter for their application to market Remoxy, an abuse-resistant controlled-release form of oxycodone. |
The Motley Fool
November 2, 2007
Brian Lawler |
A Date With Pain Pain Therapeutics prepares for a busy fourth quarter; shares have risen 30% recently in anticipation of upcoming phase 3 data results on oxycodone compound Remoxy. Investors, take note. |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants. |
The Motley Fool
May 15, 2007
Brian Lawler |
King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years. |
The Motley Fool
April 1, 2008
Brian Lawler |
A Competitive Stab at King and Pain A new, dark-horse competitor, privately held Purdue Pharma, arrives to fight King Pharma and Pain Therapeutics. |
The Motley Fool
March 1, 2007
Brian Lawler |
King Atop Its Throne After two quarters of middling revenue growth, drugmaker King Pharmaceuticals reported blowout sales and operating cash flow for its fourth quarter. |
The Motley Fool
June 11, 2008
Brian Lawler |
Pain and King Start the Countdown Who will win the race to get approval of an abuse-deterrent drug, Pain Therapeutics or King Pharmaceuticals? |
The Motley Fool
August 14, 2008
Brian Lawler |
A Potentially Painless PDUFA Date King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA. |
The Motley Fool
August 31, 2007
Brian Lawler |
4 Biotech Bets Under $10 Development stage drugmakers are among the most exciting stocks to follow. Here are four that are all worth a place on your watch list: Pharmacopeia, Pain Therapeutics, Pharmasset, and SGX Pharmaceuticals. |
The Motley Fool
July 2, 2008
Brian Lawler |
DURECT's Intriguing Little Orphan An exciting pain drug inches onward in development. |
The Motley Fool
May 5, 2008
Brian Lawler |
Good News for Abuse-Resistant Drugs Drug developers working on harder-to-abuse pain remedies, including Pain Therapeutics, King Pharmaceuticals, and Alpharma, got a guarded thumbs-up from the FDA last week. |
The Motley Fool
August 14, 2009
Brian Orelli |
The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet. |
The Motley Fool
March 3, 2009
Robert Steyer |
Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company. |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
The Motley Fool
March 21, 2007
Brian Lawler |
New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary. |
The Motley Fool
October 8, 2007
Charly Travers |
Scanning 4 Biotechs There are major events set for the following biotech companies during this quarter. Investors, take note: BioMarin Pharmaceutical... Exelixis... Neurocrine Biosciences... Pain Therapeutics... |
The Motley Fool
June 20, 2011
Brian Orelli |
Pfizer's Pain-Free FDA Approval. More to Come? Oxecta gains FDA approval. Remoxy is up next. |
The Motley Fool
July 10, 2007
Brian Lawler |
Adolor Tries Again Adolor continues work on its second drug candidate. Investors will have to wait until early 2008 for some data to sink their teeth into. |
The Motley Fool
December 9, 2008
Brian Orelli |
Presents or Coal From the FDA? Let's take a look at a few companies expecting FDA decisions this month and see whether they're more likely to get a present or a lump of coal in their marketing-application stockings. |
The Motley Fool
May 31, 2011
Brian Orelli |
Pay Attention, Biotech Investors Competitors and partners can't be ignored. |
The Motley Fool
March 30, 2005
David Nierengarten |
Soothing Results, But Pain for Investors Pain Therapeutics delivers again but its stock barely budged. What gives? |
The Motley Fool
August 29, 2011
Brian Orelli |
A Less Painful FDA Decision Johnson & Johnson gains approval of Nucynta ER. |
The Motley Fool
September 26, 2007
Brian Orelli |
4 Platform Drugmakers to Watch Platform drugmakers have the potential to develop multiple drugs for a company. Let's take a look at four companies with good prospects: Abraxis BioScience... DURECT... Halozyme... Flamel Technologies... |
BusinessWeek
June 14, 2004
Gene G. Marcial |
From Pain Therapeutics: A Better Pain Killer Remoxy, now in proof-of-concept trials, could become the replacement for the most popular opioid pain killer OxyContin, with a potential $1 billion market. |
The Motley Fool
February 26, 2007
Brian Lawler |
Endo Brings in the Dough Why buy this pharmaceutical? Investors, let me count the ways. |
Nursing
October 2009
Yvonne D'Arcy |
Overturning barriers to pain relief in older adults This article will describe how to lower the barriers to effective pain control in older patients and provide practical tips for helping them receive the full benefit from pharmacologic and nonpharmacologic therapies. |
